PrOTYPE is a locked down assay validated to Institute of Medicine standards, using NanoString technology to classify high-grade serous ovarian cancer into four defined subgroups. Future directions will include prospective–retrospective analysis and prospective clinical validation to define the predictive role of this assay and its role in influencing treatment decisions.

See related article by Talhouk et al., p. 5411

©2020 American Association for Cancer Research.
2020
American Association for Cancer Research.
You do not currently have access to this content.